Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
Recent pre-clinical work has suggested that Itraconazole has an anti-cancer effect that works
synergistically with hydroxychloroquine. This may delay the need for androgen deprivation
therapy (ADT) and its associated toxicities in men with biochemically recurrent (BCR)
prostate cancer. This study aims to determine feasibility, safety and efficacy of
suba-itraconazole (SI) in combination with hydroxychloroquine (HQ) in the treatment of
biochemically recurrent (BCR) prostate cancer as means of delaying time to commencement of
androgen deprivation therapy.